

## **Prof. Francesco Dotta**

Nato a Roma il 9/9/1960. Residente a Roma, Via Salaria 408.  
Coniugato con Elisabetta Ferretti; 2 figlie (Margherita ed Elena)

**Contatti:** U.O.C. Diabetologia, Policlinico “Le Scotte” Viale Bracci 18, 53100, Siena.  
Tel. 0577-586269, FAX: 0577-586186  
E-mail: [francesco.dotta@alice.it](mailto:francesco.dotta@alice.it); [francesco.dotta@unisi.it](mailto:francesco.dotta@unisi.it)

### **Posizione ed incarichi attuali:**

**Professore Associato Confermato**, Raggruppamento disciplinare MED/13-Endocrinologia, Facoltà di Medicina e Chirurgia, Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, Università di Siena.

**Direttore** della Scuola di Specializzazione di Endocrinologia e Malattie del Metabolismo, Università di Siena.

**Componente** della Commissione Relazioni Internazionali per l'Area 2 - Scienze Biomediche e Mediche, Università di Siena.

**Membro** del Comitato Ordinatore del Corso di Laurea Magistrale in Biotecnologie Mediche, Facoltà di Medicina e Chirurgia dell'Università di Siena.

**Membro** del Collegio dei Docenti della Scuola di Dottorato di Ricerca in Biotecnologie Mediche - Università degli Studi di Siena.

**Dirigente Medico di II Livello; Direttore dell'Unità Operativa Complessa di Diabetologia**, Dipartimento di Medicina Interna e Specialistica, Policlinico “Le Scotte”, Azienda Ospedaliera Universitaria Senese.

**Direttore dell'UOSA Dietetica Medica**, Dipartimento di Medicina Interna e Specialistica, Policlinico “Le Scotte”, Azienda Ospedaliera Universitaria Senese.

**Presidente** della Fondazione di Ricerca Biomedica “Umberto Di Mario” ONLUS.

**Segretario Generale** dell'Italian Barometer Diabetes Observatory.

**Membro** del Comitato Tecnico Scientifico del Consorzio per la Ricerca Economica Applicata (CREA) in Sanità.

**Academic Editor** di PLoS ONE.

**Associate Editor** di World Journal of Diabetes.

**Membro** dell'Editorial Board di Acta Diabetologica.

**Abilitazione Scientifica Nazionale settore concorsuale 06/D2 Endocrinologia, Nefrologia e Scienze dell'Alimentazione e del Benessere – I Fascia (Bando 2012)**

**Abilitazione Scientifica Nazionale settore concorsuale 06/B1 Medicina Interna – I Fascia (Bando 2012)**

### **Formazione ed Attività Scientifica**

1985 Laurea in Medicina e Chirurgia (110/110 e lode), Università di Roma “La Sapienza”.

1989 Specializzazione in Endocrinologia (70/70 e lode), Università di Roma “La Sapienza”.

1986-89 Ricercatore presso il Joslin Diabetes Center, Harvard University School of Medicine, Boston - Usa.

1990-99 Funzionario Tecnico, Cattedra di Medicina Costituzionale ed Endocrinologia, Università di Roma “La Sapienza”.

1999-2000 Ricercatore Confermato, Raggruppamento disciplinare F07E-Endocrinologia, Facoltà di Medicina e Chirurgia, Dipartimento di Scienze Cliniche, Università di Roma “La Sapienza”.

2000-2003 Professore Associato SSD MED13-Endocrinologia, Università di Roma “La Sapienza”, Roma.

1999-2001 Membro della Commissione Scientifica della Società Italiana di Endocrinologia.

2002-2006 Membro della Commissione Scientifica della Società Italiana di Diabetologia.

2005-2009 Membro e Presidente della Sezione Toscana della Società Italiana di Diabetologia.

2005-2009 Membro del Medical Science Review Committee, Juvenile Diabetes Research Foundation (JDRF).

2005-2010 Associate Editor di Nutrition, Metabolism and Cardiovascular Disease.

2005-2009 Membro dell'Editorial Board di Journal of Clinical Endocrinology and Metabolism.

2005- Presidente della Fondazione di Ricerca Biomedica "Umberto Di Mario" ONLUS.

2007- Commissario per la valutazione dei Progetti Ordinari di Ricerca del Ministero della Salute.

2007- Membro dell'Editorial Board di Acta Diabetologica.

2007- Referee per la valutazione dei Progetti di Ricerca del Ministero della Ricerca del Belgio.

2008 Referee per la valutazione dei Progetti di Ricerca dell'Istituto Nazionale per la Sanità e Ricerca Medica francese (INSERM).

2008 Commissario per la valutazione dei Progetti Ordinari di Ricerca del Ministero della Salute.

2008-2012 Membro del Consiglio Direttivo della Società Italiana di Diabetologia.

2008-2010 Membro della Commissione Scientifica della Società Italiana di Diabetologia.

2010-2012 Coordinatore della Commissione Scientifica della Società Italiana di Diabetologia.

2011 Segretario Generale della Commissione Scientifica dell'Italian Barometer Diabetes Observatory.

2012 Membro dell'Editorial Board di PLoS ONE.

2013-2019 Componente della Commissione Relazioni Internazionali per l'Area 2 - Scienze Biomediche e Mediche, Università di Siena.

2013 Membro dell'Editorial Board dell'American Journal of Clinical and Experimental Immunology .

2013 Direttore della Scuola di Specializzazione di Endocrinologia e Malattie del metabolismo, Università di Siena.

2013-2015 Componente Gruppo di Lavoro ANVUR su Indicatori di Terza Missione

2013 **Abilitazione Scientifica Nazionale settore concorsuale 06/B1 Medicina Interna – I Fascia (Bando 2012)**

2014 **Abilitazione Scientifica Nazionale settore concorsuale 06/D2 Endocrinologia, Nefrologia e Scienze dell' Alimentazione e del Benessere – I Fascia (Bando 2012)**

2015 Direttore dell'UOSA Dietetica Medica, Dipartimento di Medicina Interna e Specialistica, Policlinico "Le Scotte", Azienda Ospedaliera Universitaria Senese.

### **Riconoscimenti Scientifici**

1986 Borsa di Studio: Istituto Pasteur, Fondazione Cenci Bolognetti.

1987 Fellowship Award della Juvenile Diabetes Foundation International.

1988 Premio "Travel Grant" della International Diabetes Federation. , "Outstanding abstract Award" della Immunology and Diabetes Workshop.

1989 Premio Bayer della European Society of Clinical Investigation., Premio "Travel Grant" della European Association for the Study of Diabetes.

1990 "Outstanding abstract Award" della Immunology and Diabetes Workshop.

1990 Premio Bracco della Società Italiana di Endocrinologia.

1994 Premio Novo Nordisk Hagedorn della Società Italiana di Diabetologia.

2006 Outstanding Reviewer Recognition Award della Endocrine Society - USA.

2008 Kugel Award - Juvenile Diabetes Research Foundation International.

2012 August and Marie Krogh Medal – Ambasciata di Danimarca.

2013 nPOD Investigator Award – Juvenile Diabetes Foundation International

2013 Inserito nell'elenco Top Italian Scientists (TIS) della VIA-Academy.

### **ATTIVITÀ IN RIVISTE SCIENTIFICHE**

**Associate Editor** di Nutrition, Metabolism & Cardiovascular Diseases (dal 2005-2010).

**Membro dell'Editorial Board** del Journal of Clinical Endocrinology and Metabolism (2005-2009).

**Membro dell'Editorial Board** del World Journal of Diabetes (2010-2015).

**Membro dell'Editorial Board** di Acta Diabetologica (dal 2007).

**Academic Editor** di PLoS ONE (dal 2012).

**Referee delle seguenti riviste scientifiche:**

Proceedings of the National Academy of Sciences USA, Diabetes, Diabetologia, Journal of Clinical Endocrinology and Metabolism, Endocrinology, Molecular Endocrinology, Cell Death and Differentiation, European Journal of Immunology, Clinical Immunology, European Journal of Endocrinology, Diabetes Metabolism Research and Reviews, Diabetes Obesity & Metabolism, Cell Death and Differentiation, Clinical Immunology, Diabetes Metabolism Research and Reviews, Nutrition Metabolism and Cardiovascular Diseases, Transplantation, Journal of Autoimmunity, Journal of Endocrinological Investigation, Hormone Research, Clinical Chemistry, Autoimmunity, Acta Diabetologica, PLoS ONE, American Journal of Medicine.

## ATTIVITÀ DI RICERCA SPERIMENTALE E CLINICA

Il prof. Dotta dirige un gruppo di ricerca di 10 unità di personale laureato (medici e biologi, dottorandi o dottori in ricerca, specialisti in formazione) e 2 non laureato (tecnici di laboratorio) impegnati, anche attraverso periodici soggiorni all'estero, in progetti di ricerca mirati alla caratterizzazione di vari aspetti patogenetici e fisiopatologici del diabete mellito e delle sue complicanze, della sindrome metabolica, delle complicanze metaboliche post-trapianto e delle endocrinopatie autoimmuni.

### Finanziamenti per la Ricerca:

1994-1995 Società Italiana di Diabetologia - "Geni di suscettibilità nelle malattie autoimmuni: Genetica della risposta mediata dagli autoanticorpi nel diabete mellito insulino-dipendente. Importanza per la predizione e prevenzione della malattia".

1995-1996 Telethon - "Identification of novel B-cell epitopes in sera of insulin-dependent diabetic patients using random phage libraries: Relevance for disease prediction and prevention".

Juvenile Diabetes Research Foundation International - "Search for novel T-cell epitopes in beta cell autoimmunity using random phage peptide libraries".

1997-1998 Telethon - "Cell-mediated autoimmunity, -cell dysfunction and islet regeneration at the onset of type 1 diabetes".

1999-2000 Juvenile Diabetes Research Foundation International - "Abnormalities in apoptosis signaling underlining autoimmune diabetes".

2000 Ministero della Sanità - "Ruolo delle cellule immuno-regolatorie intestinali in modelli sperimentali di diabete mellito insulino-dipendente".

2001 MIUR - 40% - "Regolazione dell'apoptosi beta-cellulare nel danno insulare immuno-mediato"- Responsabile di Unità Operativa nel Progetto Coordinato "Meccanismi molecolari della disfunzione della beta-cellula pancreatica" - (Coordinatore Prof. R. Lauro) (prot. 2001063815).

MIUR - Progetti di Facoltà - "Meccanismi di morte cellulare nel danno insulare indotto da citochine".

2002 Ministero della Sanità - "Caratterizzazione di epitopi autoantigenici nel diabete di tipo 1 nel bambino e nell'adulto".

2003 Ministero della Sanità - "Modulazione dell'espressione genica a proteica in corso di danno insulare mediato da citochine".

Ministero della Sanità - "Disregolazione del sistema immunitario: analisi dei meccanismi cellulari che intervengono nelle patologie autoimmuni e da allergia".

2004-2008 6<sup>th</sup> Frame Programme of the European Union - "Coordination action on the aetiology, pathology and prediction of type 1 diabetes in Europe" (TONECA).

2004 Ministero della Salute - "Nuove strategie cellulari e molecolari per la terapia del diabete mellito".

2005-2007 Ministero della Salute - "Meccanismi di Danno e Rigenerazione della Beta Cellula Pancreatica".

2006-2007 MIUR - PRIN 2006 - "Strategie di espansione, caratterizzazione e differenziamento beta-cellulare di precursori provenienti da isole pancreatiche umane e da placenta: ruolo della via di Hedgehog".

2007-2009 FORISID - "Pathways and mechanisms of beta-cell regeneration and proliferation in type 1 and type 2 diabetes".

2009-2012 MIUR - PRIN 2008 - Coordinatore Nazionale del progetto "Terapia cellulare del diabete mellito: Meccanismi molecolari e segnali extracellulari nella regolazione della funzione e della massa cellulare dell'isola pancreatica." Responsabile Scientifico dell'Unità di ricerca "Strategie di espansione, caratterizzazione e differenziamento beta-cellulare di precursori provenienti da isole pancreatiche umane e da placenta: ruolo della via di Hedgehog".

2009-2015 7<sup>th</sup> Frame Programme of the European Union - Project number: 241447 "Natural immunomodulators as novel immunotherapies for type 1 diabetes" (NAIMIT). Responsible of Research Unit and Work Package

Leader.

2010-2012 Regione Toscana - Programma per la Ricerca Regionale in Materia di Salute 2009 - “Pancreatic islet microRNAs as therapeutic target in type 2 diabetes”.

2010-2016 7<sup>th</sup> Frame Programme of the European Union - Project number: 261441 “Persistent virus infection as a cause of pathogenic inflammation in type 1 diabetes - an innovative research program of biobanks and expertise” (PEVNET). Responsible of Research Unit and Work Package Leader.

2010-2012 Fondazione Roma - “Molecular mechanisms in the pathogenesis of type 2 diabetes mellitus and its cardiovascular complications”.

2010-2012 Fondazione MPS - “Scenning per la diagnosi precoce di diabete mellito tipo 1 e di malattia celiaca mediante determinazioni autoanticorpali nella saliva: studio nella popolazione scolastica elementare di Siena”.

2011-2013 Fondazione CARIPISA - “Ruolo del nano incapsulamento mediante multistrati, di nanostrutture con proprietà antiinfiammatorie, e del posizionamento guidato mediante nanoparticelle nel trapianto di isole pancreatiche per il trattamento del diabete di tipo 1”.

2011-2016 Juvenile Diabetes Research Foundation International: nPOD - “Network of pancreatic organ donors”.

2012-2015 Juvenile Diabetes Research Foundation International: nPOD-V - “nPOD Viral Work Group”.

2012-2017 National Institutes of Health NIH Department of Health and Human Services Public Health Services “Assessment of cytokines in human islets from patients with diabetes”.

2012-2016 MIUR - PRIN 2010-2011 - “Nuovi aspetti della fisiopatologia del diabete mellito e potenziali applicazioni terapeutiche.”

2015-2017 Fondazione Roma - “Non communicable diseases in the elderly: Circulating microRNAs and long non coding RNAs as novel biomarkers of response to therapy in metabolic diseases”.

2015- 2022 HORIZON 2020-JTI-IMI2-2014-01 of the European Union - Project number: 115797 - “Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes” (INNODIA). Coordinator of European nPOD Initiative.

### **Partecipazione a trials clinici:**

Partecipazione (e coordinamento a livello nazionale) a numerosi protocolli internazionali di sperimentazione clinica in Fase II e Fase III su nuovi farmaci per la terapia del diabete mellito tipo 1 e tipo 2, per la prevenzione del diabete tipo 1, per la prevenzione della nefropatia diabetica e per il trattamento della dislipidemia nei soggetti con diabete mellito.

## **PUBBLICAZIONI SCIENTIFICHE**

(su riviste peer-reviewed)

**I.F. Totale: 909.8**

**H-index: 38**

**Citazioni: 8023**

1. Amenta F, Cavallotti C, **Dotta F**, Ferrante F, Spinelli F, Vatrella F. (1983) The autonomic innervation of the human greater saphenous vein. Acta Histochemica; 72: 111-116. **(I.F. 1.714)**
2. Gargiulo P, Di Mario U, **Dotta F**, Kennedy R, Guy K, Pachì A, Fallucca F. (1986) Activated T cells in normal pregnant women and neonates. Eur J Obstet Gynecol Reprod Biol; 23: 127-135. **(I.F. 1.695)**
3. Di Mario U, **Dotta F**, Gargiulo P, Sutherland J, Andreani D, Guy K, Pachì A, Fallucca F. (1987) Immunology in diabetic pregnancy: activated T cells in diabetic mothers and neonates. Diabetologia; 30(2): 66-71. **(I.F. 6.671)**
4. **Dotta F**, Gargiulo P, Tiberti C, Pachi A, Fallucca F, Andreani D, Di Mario U. (1987) Humoral and cellular immune abnormalities in neonates of diabetic mothers: any pathological role? Exp Clin Endocrinol; 89(3): 333-339. **(I.F. 1.555)**

5. Di Mario U, **Dotta F**, Gargiulo P, Fallucca F, Pachì A, Andreani D. (1987) Immunopathology of diabetic mothers and their infants: a contribution to the understanding of islet autoimmunity. In: "The immunology of diabetes". Jaworski (ed), Elsevier Science Publisher B.V.: 137-142.
6. Dib SA, Colman PG, **Dotta F**, Tautkus M, Rabizadeh A, Eisenbarth GS. (1987) Expression of cytoplasmic islet cell antigens by rat pancreas. Diabetes; 36(8): 982-985. **(I.F. 8.095)**
7. **Dotta F**, Nayak RC, Dib SA, Di Bella E, Krisch K, Posillico JT, Ricker AT, Di Mario U, Eisenbarth GS. (1988) A novel neuroendocrine cell surface glycoprotein: identification, isolation and initial characterization. Endocrinology; 122(4): 1263-1268. **(I.F. 4.503)**
8. Di Mario U, **Dotta F**, Crisa L, Anastasi E, Andreani D, Dib SA, Eisenbarth GS. (1988) Circulating anti-immunoglobulin antibodies in recent-onset type 1 diabetic patients. Diabetes; 37(4): 462-466. **(I.F. 8.095)**
9. Eisenbarth GS, Vardi, Ziegler AG, Colman PG, Nayak RC, **Dotta F**, Jackson RA, Fujii S, Ricker AT, Rabinowe SL, Ikegami H, Soeldner S, Hattori M. (1988) Lessons from the NOD mouse and the BB rat: similarities and contrasts. In: "Animal models in diabetes". Renold AE and Shafrir E (eds); John Libbey, London: 120-123.
10. Colman PG, Di Mario U, Rabizadeh A, **Dotta F**, Anastasi E, Eisenbarth GS. (1988) A prozone phenomenon interferes in islet cell antibody detection: direct comparison of two methods in subjects at risk of diabetes and in insulin dependent diabetics at onset. J Autoimmun; 1(2): 109- 117. **(I.F. 8.410)**
11. Dib SA, Colman PG, **Dotta F**, Tautkus M, Rabizadeh A, Eisenbarth GS. (1988) Assay for cytoplasmic islet cell antibodies using two-color immunofluorescence and rat pancreas. Adv Exp Med Biol; 246: 63-67. **(I.F. 1.958)**
12. **Dotta F**, Eisenbarth GS. (1989) Type 1 diabetes mellitus: a predictable autoimmune disease with interindividual variation in the rate of beta cell destruction. Clin Immunol Immunopathol; 50: 85-95. **(I.F. 3.672)**
13. **Dotta F**, Colman PG, Lombardi D, Scharp DW, Andreani D, Pontieri GM, Di Mario U, Lenti L, Eisenbarth GS, Nayak RC. (1989) Ganglioside expression in human pancreatic islets. Diabetes; 38(11): 1478-1483. **(I.F. 8.095)**
14. Gardner SL, **Dotta F**, Nayak RC, George KL, Eisenbarth GS, Halban PA. (1989) Modulation by sodium butyrate of the differentiated status of a clonal pancreatic B-cell line (RIN). Diabetes Res; 12(2): 93-99. **(I.F. 2.538)**
15. Russo E, Jackson RA, **Dotta F**, Lipes MA, Castano L, Eisenbarth GS. (1990) Type 1 diabetes as a "Mendelian" and "regulated" immune process. in: "Molecular biology of autoimmunity". A.G. Demaine, J. Banga, A.M.McGregor (eds); Springer-Verlag, London: 351-362.
16. Eisenbarth GS, Jackson RA, Ziegler R, Castano L, Bleich D, **Dotta F**. (1990) Predizione e prevenzione del diabete di tipo 1. Il Diabete; 2: 29-34.
17. **Dotta F**, Pozzilli P. (1990) Are islet cell antigens gangliosides? Intl Diab Monitor; 2: 2-3.
18. **Dotta F**, Peterson LB, Previti M, Metzger J, Tiberti C, Anastasi E, Zoppitelli, Wicker LS, Di Mario U. (1992) Pancreatic islet ganglioside expression in nonobese diabetic mice: comparison with C57BL/10 mice and changes after autoimmune beta-cell destruction. Endocrinology; 130(1): 37- 42. **(I.F. 4.503)**
19. Rotella C, **Dotta F**, Mannucci E, Di Mario U. (1992) Autoantigens in thyroid and islet autoimmunity: similarities and differences. Autoimmunity; 12(3): 223-237. **(I.F. 2.714)**
20. Previti M, **Dotta F**, Pontieri GM, Di Mario U, Lenti L. (1992) Determination of gangliosides by high-performance liquid chromatography with photodiode-array detection. J Chromat; 605: 221-225. **(I.F. 4.169)**
21. Wicker LS, Appel MC, **Dotta F**, Pressey A, Miller BJ, DeLarato NH, Fischer PA, Boltz RC, Peterson LB. (1992) Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulinitis and cyclophosphamide-induced diabetes. J Exp Med; 176(1): 67-77. **(I.F. 12.515)**

22. Pozzilli P, Buzzetti R, **Dotta F**, Andreani D. (1992) Acute onset of seeming IDDM in an AIDS patient. Diabetes Care; 15(11): 1824-1825. **(I.F. 8.420)**
23. Di Mario U, **Dotta F**. (1992) Natural history and prediction of type 1 diabetes. Ann Ig; 4: 153-157.
24. **Dotta F**, Tiberti C, Previti M, Anastasi E, Andreani D, Lenti L, Pontieri GM, Gianani R, Appel MC, Eisenbarth GS, Di Mario U. (1993) Rat pancreatic ganglioside expression: differences between a model of autoimmune islet B cell destruction and a normal strain. Clin Immunol Immunopathol; 66(2): 143-149. **(I.F. 3.672)**
25. Anastasi E, Tiberti C, Sensi M, Ponte E, Filippetti R, **Dotta F**, Vecci E, Fiori MG, Di Mario U. (1993) Pancreatic gangliosides delay the onset of insulinitis and hyperglycaemia in the low-dose streptozotocin mouse model. Scand J Immunol; 37(3): 308-313. **(I.F. 1.739)**
26. **Dotta F**, Dionisi S, Lollobrigida L, Previti M. (1993) Autoanticorpi ed autoantigeni in un modello animale di distruzione  $\beta$  cellulare: il topo NOD. Giornale It. Diabetol; Suppl.1: 63-68.
27. Di Mario U, **Dotta F**. (1993) Modulation of antigen expression in relation to intervention strategies in type 1 diabetes. Diabetes Metab Rev; 9(4): 245-249. **(I.F. 3.553)**
28. **Dotta F**, Anastasi E, Tiberti C, Di Mario U. (1994) Autoantigens in type 1 diabetes mellitus. J Endocrinol Invest; 17(7): 497-508. **(I.F. 1.448)**
29. Dionisi S, **Dotta F**. (1994) Can we replace cytoplasmic ICA determination in diabetes prediction? Diab Prev Ther; 8: 36-37.
30. La Mancusa R, Alessandri C., Basili S., Violi F., Ferroni P., Gazzaniga PP., Cordova C., **Dotta F**., Tarquini S., Simeoni S., Pettirossi G., Vieri M., Di Palma P., Cara D., Scodanibbio C., Maurelli M., Ferro D., Saliola M., Pulcinelli F., Riondino S. (1994) Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group. Thrombosis and Haemostasis, 72: 343-346. **(I.F. 4.98)**
31. Tiberti C, **Dotta F**, Anastasi E, Torresi P, Multari G, Vecci E, Andreani D, Di Mario U. (1995) Anti-ganglioside antibodies in new onset type 1 diabetic patients and high risk subjects. Autoimmunity; 22: 43-48. **(I.F. 2.714)**
32. **Dotta F**, Previti M, Lenti L, Dionisi S, Casetta B, D'Erme M, Eisenbarth GS, Di Mario U. (1995) GM2-1 pancreatic islet ganglioside: identification and characterization of a novel islet-specific molecule. Diabetologia; 38(9): 1117-1121. **(I.F. 6.671)**
33. **Dotta F**, Di Mario U. (1996) Antigenic determinants in type 1 diabetes mellitus. Review article. APMIS; 104(11): 769-774. **(I.F. 2.042)**
34. **Dotta F**, Gianani R, Previti M, Lenti L, Dionisi S, D'Erme M, Eisenbarth GS, Di Mario U. (1996) Autoimmunity to the GM2-1 islet ganglioside before and the onset of type 1 diabetes. Diabetes; 45(9): 1193-1196. **(I.F. 8.095)**
35. Mennuni C, Santini C, **Dotta F**, Farilla L, Di Mario U, Fierabracci A, Bottazzo G, Cortese R, Luzzago A. (1996) Selection of phage-displayed peptides mimicking type 1 diabetes-specific epitopes. J Autoimmunity; 9(3): 431-436. **(I.F. 8.410)**
36. Cavallo MG, **Dotta F**, Monetini L, Dionisi S, Previti M, Valente L, Toto A, Di Mario U, Pozzilli P. (1996) Beta-cell markers and autoantigen expression by a human insulinoma cell line: similarities to native beta cells. J Endocrinol; 150(1): 113-120. **(I.F. 3.718)**
37. **Dotta F**, Dionisi S, Farilla L, Di Mario U. (1996) The use of immunological markers in IDDM after more than 20 years from ICA description. Diabetes Metab Rev; 12(2): 121-126. **(I.F. 3.553)**
38. **Dotta F**, Dionisi S, Misasi R, Tiberti C, Anastasi E, Carabba B, Farilla L, Di Mario U. (1996) Ganglioside antigens in autoimmune diabetes. Diabetes Nutr Metab; 9: 215-220. **(I.F. 0.7)**
39. **Dotta F**. (1996) Highlights from the American Diabetes Association's Symposium on prevention of type 1 diabetes in the general population. Diab Prev Ther; 10: 28-29.
40. Misasi R, Dionisi S, Farilla L, Carabba B, Lenti L, Di Mario U, **Dotta F**. (1997) Gangliosides and

autoimmune diabetes. Diabetes Metab Rev; 13(3): 163-179. (I.F. 3.553)

41. **Dotta F**, Falorni A, Tiberti C, Dionisi S, Anastasi E, Torresi P, Lernmark A, Di Mario U. (1997) Autoantibodies to the GM2-1 islet ganglioside and to GAD-65 at type 1 diabetes onset. J Autoimmunity; 10(6): 585-588. (I.F. 8.410)
42. Tiberti C, Falorni A, Torresi P, Vecci E, Anastasi E, **Dotta F**, Di Mario U. (1997) A new solid-phase radioimmunoassay to detect anti-GAD65 autoantibodies. J Immunol Methods; 207(2): 107-113. (I.F. 1.820)
43. Mennuni C, Santini C, Lazzaro D, **Dotta F**, Farilla L, Fierabracci A, Bottazzo GF, Di Mario U, Cortese R, Luzzago A. (1997) Identification of a novel type 1 diabetes-specific epitope by screening phage libraries with sera from pre-diabetic patients. J Mol Biol; 268(3): 599-606. (I.F. 4.333)
44. Dionisi S, **Dotta F**, Diaz-Horta O, Carabba B, Viglietta V, Di Mario U. (1997) Target antigens in autoimmune diabetes: pancreatic gangliosides. Ann Ist Super Sanità; 33(3): 433-435. (I.F. 1.111)
45. **Dotta F**, Previti M, Neerman-Arbez M, Dionisi S, Cucinotta D, Lenti L, Di Mario U, Halban PA. (1998) The GM2-1 ganglioside islet autoantigen in insulin-dependent diabetes mellitus is expressed in secretory granules and is not beta-cell specific. Endocrinology; 139(1): 316-319. (I.F. 4.503)
46. Di Mario U, **Dotta F**. (1998) Beta-cell autoimmunity 1998. Diabetes Metab Rev; 14(1): 1-2. (I.F. 3.553)
47. Anastasi E, **Dotta F**, Tiberti C, Vecci E, Ponte E, Di Mario U. (1999) Insulin prophylaxis down-regulates islet antigen expression and islet autoimmunity in the low-dose Stz mouse model of diabetes. Autoimmunity; 29(4): 249-256. (I.F. 2.714)
48. **Dotta F**, Dionisi S, Viglietta V, Tiberti C, Matteoli MC, Cervoni M, Bizzarri C, Marietti G, Testi M, Multari G, Lucentini L, Di Mario U. (1999) T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus. Eur J Endocrinol; 141(3): 272-278. (I.F. 4.069)
49. Anastasi E, Ponte E, Gradini R, Bulotta A, Sale P, Tiberti C, Okamoto H, **Dotta F**, Di Mario U. (1999) Expression of Reg and cytokeratin 20 during ductal cell differentiation and proliferation in a mouse model of autoimmune diabetes. Eur J Endocrinol; 141(6): 644-652. (I.F. 4.069)
50. Tiberti C, Buzzetti R, Anastasi E, **Dotta F**, Vasta M, Petrone A, Cervoni M, Torresi P, Vecci E, Multari G, Di Mario U. (2000) Autoantibody negative new onset of type 1 diabetic patients lacking high risk HLA alleles in a caucasian population: are these type 1b diabetes cases? Diabetes Metab Res Rev; 16(1): 8-14. (I.F. 3.553)
51. Marchetti P, **Dotta F**, Ling Z, Lupi R, Del Guerra S, Santangelo C, Realacci M, Marselli L, Di Mario U, Navalesi R. (2000) Function of pancreatic islets isolated from a type 1 diabetic patient. Diabetes Care; 23(5): 701-703. (I.F. 8.420)
52. Cilio CM, Bosco S, Moretti C, Farilla L, Savignoni F, Colarizi P, Multari G, Di Mario U, Bucci G, **Dotta F**. (2000) Congenital autoimmune diabetes mellitus. New Engl J Med; 342(20): 1529-1531. (I.F. 55.873)
53. Farilla L, **Dotta F**, Di Mario U, Rapoport B, McLachlan SM. (2000) Presence of interleukin 4 or interleukin 10, but not both cytokines, in pancreatic tissue of two patients with recently diagnosed diabetes mellitus type I. Autoimmunity; 32(3): 161-166. (I.F. 2.714)
54. Del Guerra S, Lupi R, **Dotta F**, Marselli L, Lencioni C, Santangelo C, Realacci M, Carmellini M, Mosca F, Navalesi R, Marchetti P. (2000) Effects of prolonged exposure to pancreatic glucagon on the function, antigenicity and survival of isolated human islets. Diabetes Metab Res Rev; 16(4): 281-286. (I.F. 3.553)
55. Piro S, Lupi R, **Dotta F**, Patanè G, Rabuazzo MA, Marselli L, Santangelo C, Realacci M, Del Guerra S, Purrello F, Marchetti P. (2001). Bovine islets are less susceptible than human islets to damage by human cytokines. Transplantation; 71(1): 21-26. (I.F. 3.828)
56. Marselli L, **Dotta F**, Piro S, Santangelo C, Masini M, Lupi R, Realacci M, Del Guerra S, Mosca F, Boggi U, Purrello F, Navalesi R, Marchetti P. (2001) Th2 cytokines have a partial, direct protective effect on the function and survival of isolated human islets exposed to combined proinflammatory and Th1 cytokines. J Clin Endocrinol Metab; 86(10): 4974-4978. (I.F. 6.209)



57. Trincavelli ML, Marselli L, Falleni A, Gremigni V, Ragge E, **Dotta F**, Santangelo C, Marchetti P, Lucacchini A, Martini C. (2002) Upregulation of mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced damage of human pancreatic islets. J Cell Biochem; 84(3): 636-644. **(I.F. 3.263)**
58. Miao D, Yu L, Tiberti C, Cuthbertson DD, Rewers M, Di Mario U, Eisenbarth GS, **Dotta F**. (2002) ICA512 (IA-2) epitope specific assays distinguish transient from diabetes associated autoantibodies. J Autoimmun; 18(2): 191-196. **(I.F. 8.410)**
59. **Dotta F**, Vendrame F. (2002) Neonatal syndromes of polyendocrinopathy. Endocrinol Metab Clin North Am; 31(2): 283-293. **(I.F. 3.404)**
60. Lupi R, **Dotta F**, Marselli L, Del Guerra S, Masini M, Santangelo C, Patané G, Boggi U, Piro S, Anello M, Bergamini E, Mosca F, Di Mario U, Del Prato S, Marchetti P. (2002) Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes; 51(5): 1437-1442. **(I.F. 8.095)**
61. Farilla L, Tiberti C, Luzzago A, Yu L, Eisenbarth GS, Cortese R, **Dotta F**, Di Mario U. (2002) Application of phage display peptide library to autoimmune diabetes: identification of IA-2/ICA512bdc dominant autoantigenic epitopes. Eur J Immunol; 32(5): 1420-1427. **(I.F. 4.034)**
62. Davidson J, Wilkinson A, Dantal J, **Dotta F**, Haller H, Hernandez D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC; International Expert Panel. (2003) New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an International expert panel meeting. Barcelona, Spain, 19 february 2003. Transplantation; 75(10): 3-24. **(I.F. 3.828)**
63. Tiberti C, Bao F, Bonamico M, Verrienti A, Picarelli A, Di Tola M, Ferri M, Vecci E, **Dotta F**, Eisenbarth GS, Di Mario U. (2003) Celiac disease-associated transglutaminase autoantibody target domains at diagnosis are age and sex dependent. Clin Immunol; 109(3): 318-324. **(I.F. 3.672)**
64. Lupi R, Marselli L, Dionisi S, Del Guerra S, Boggi U, Del Chiaro M, Lencioni C, Bugliani M, Mosca F, Di Mario U, Del Prato S, **Dotta F**, Marchetti P. (2004) Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients. Diabetes Metab Res Rev; 20(3): 246-251. **(I.F. 3.553)**
65. Hui H, **Dotta F**, Di Mario U, Perfetti R. (2004) Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death. J Cell Physiol; 200(2): 177-200. **(I.F. 3.839)**
66. Falorni A, Laureti S, De Bellis A, Zanchetta R, Tiberti C, Arnaldi G, Bini V, Beck-Peccoz P, Bizzarro A, **Dotta F**, Mantero F, Bellastella A, Betterle C, Santeusano F; SIE Addison Study Group. (2004) Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J Clin Endocrinol Metab; 89(4): 1598-1604. **(I.F. 6.209)**
67. Marselli L, Trincavelli L, Santangelo C, Lupi R, Del Guerra S, Boggi U, Falleni A, Gremigni V, Mosca F, Martini C, **Dotta F**, Di Mario U, Del Prato S, Marchetti P. (2004) The role of peripheral benzodiazepine receptors on the function and survival of isolated human pancreatic islets. Eur J Endocrinol; 151(2): 207-214. **(I.F. 4.069)**
68. **Dotta F**, Marchetti P. (2004) Pathological changes in human insulinitis. Curr Opin Endocr & Diabetes; 11: 82-84. **(I.F. 3.367)**
69. Vendrame F, Zappaterreno A, **Dotta F**. (2004) Markers of beta cell function in type 1 diabetes mellitus. Minerva Med; 95(2): 79-84. **(I.F. 0.913)**
70. Vendrame F, Santangelo C, Misasi R, Dionisi S, Gizzi C, Realacci M, Grassetti D, Di Mario U, **Dotta F**. (2005) Defective lymphocyte caspase-3 expression in type 1 diabetes mellitus. Eur J Endocrinol; 152(1): 119-125. **(I.F. 4.069)**
71. Santangelo C, Scipioni A, Marselli L, Marchetti P, **Dotta F**. (2005) Suppressor of cytokine signaling gene expression in human pancreatic islets: modulation by cytokines. Eur J Endocrinol; 152(3): 485-489. **(I.F. 4.069)**

72. Putnam AL, Vendrame F, **Dotta F**, Gottlieb PA. (2005) CD4+CD25 high regulatory T cells in human autoimmune diabetes. J Autoimmun; 24(1): 55-62. (I.F. 8.410)
73. Tiberti C, Verrienti A, Fiore B, Yu L, Eisenbarth GS, **Dotta F**, Di Mario U. (2005) IA-2 combined epitope assay: a new, highly sensitive approach to evaluate IA-2 humoral autoimmunity in type 1 diabetes. Clin Immunol; 115(3): 260-267. (I.F. 3.672)
74. Anastasi E, Santangelo C, Bulotta A, **Dotta F**, Argenti B, Mincione C, Gulino A, Maroder M, Perfetti R, Di Mario U. (2005) The acquisition of an insulin-secreting phenotype by HGF-treated rat pancreatic ductal cells (ARIP) is associated with the development of susceptibility to cytokine-induced apoptosis. J Mol Endocrinol; 34(2): 367-376. (I.F. 3.081)
75. Wilkinson A, Davidson J, **Dotta F**, Home P, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregrosa JV, Uchida K, Valentine F, Villamil F, Vincenti F, Wissing M. (2005) Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant; 19(3): 291-298. (I.F. 1.522)
76. Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, Corneli RB, Ferretti E, Gulino A, Grasso F, De Simone C, Di Mario U, Falorni A, Boirivant, **Dotta F**. (2005) Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia; 48(8): 1565-1575. (I.F. 6.671)
77. **Dotta F**, Fondelli C, Vendrame F, Gianani R. (2005) Pathological changes in human islets. Curr Opin. Endocr & Diabetes; 12: 285-290. (I.F. 3.367)
78. Fourlanos S, **Dotta F**, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC. (2005) Latent Autoimmune Diabetes in Adults (LADA) should be less latent. Diabetologia; 48(11): 2206-2212. (I.F. 6.671)
79. **Dotta F**, Fondelli C, Di Mario U. (2005) Type 1 diabetes mellitus as a polygenic multifactorial disease: immunopathogenic mechanisms of beta-cell destruction. Acta Biomed; 76: 14-18.
80. Roep B, Van Halteren A, Boggi U, Marchetti P, **Dotta F**. (2005) Islet autoreactivity in pancreas draining lymph nodes in recent onset type 1 diabetes. Endocr J; 52: 162-164. (I.F. 1.997)
81. Tiberti C, Bonamico M, **Dotta F**, Verrienti A, Di Tola M, Liu E, Ferri M, Nenna R, Picarelli A, Eisenbarth GS. (2006) Evidence of a selective epitope loss of anti-transglutaminase immunoreactivity in gluten-free diet celiac sera: a new tool to distinguish disease-specific immunoreactivities. Clin Immunol; 121(1): 40-46. (I.F. 3.672)
82. Vendrame F, Segni M, Grassetti D, Tellone V, Augello G, Trischitta V, Torlontano M, **Dotta F**. (2006) Impaired caspase-3 expression by peripheral T cells in chronic autoimmune thyroiditis and in autoimmune polyendocrine syndrome-2. J Clin Endocrinol Metab; 91(12): 5064-5068. (I.F. 6.209)
83. **Dotta F**, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, Mosca F, Boggi U, Onetti Muda A, Del Prato S, Elliott JF, Covacci A, Rappuoli R, Roep BO, Marchetti P. (2007) Coxsackie B4 virus infection of beta cells and natural killer cell insulinitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA; 104(12): 5115-5120. (I.F. 9.674)
84. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML Bazzigaluppi E, **Dotta F**, Bosi E. (2007) High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care; 30(4): 932-938. (I.F. 8.420)
85. Gallo R, Gambelli F, Gava B, Sasdelli F, Tellone V, Masini M, Marchetti P, **Dotta F**, Sorrentino V. (2007) Generation and expansion of multipotent mesenchymal progenitor cells from cultured human pancreatic islets. Cell Death Differ; 14(11): 1860-1871. (I.F. 8.184)
86. Giannakakis K, Massella L, Grassetti D, **Dotta F**, Perez M, Onetti-Muda A. (2007) Type VII collagen in Alport syndrome. Nephrol Dial Transplant; 22(12): 3501-3507. (I.F. 3.577)
87. Marchetti P, **Dotta F**, Lauro D, Purrello F. (2008) An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Regul Pept; 146(1-3): 4-11. (I.F. 1.833)
88. Bolli G, **Dotta F**, Rochotte E, Cohen SE. (2008) Efficacy and tolerability of vildagliptin vs. pioglitazone

- when added to metformin: a 24-week, randomized, double-blind study. *Diabetes Obes Metab*; 10(1): 82-90. (I.F. 6.360)
89. Egan CG, Lavery R, Caporali F, Fondelli C, Laghi-Pasini F, **Dotta F**, Sorrentino V. (2008) Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. *Diabetologia*; 51(7): 1296-1305. (I.F. 6.671)
90. Vendrame F, Verrienti A, Parlapiano C, Filetti S, **Dotta F**, Morano S. (2008) Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis. *Ann Clin Biochem*; 45(Pt 2): 218-220. (I.F. 2.335)
91. Tiberti C, Giordano C, Locatelli M, Bosi E, Bottazzo GF, Buzzetti R, Cucinotta D, Galluzzo A, Falorni A, **Dotta F**. (2008) Identification of tyrosine phosphatase 2 (256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. *Diabetes*; 57(5): 1276-1283. (I.F. 8.095)
92. Bonato V, Barni R, Cataldo D, Collini A, Ruggieri G, De Bartolomeis C, **Dotta F**, Carmellini M. (2008) Analysis of posttransplant diabetes mellitus prevalence in a population of kidney transplant recipients. *Transplant Proc*; 40(6): 1888-1890. (I.F. 0.982)
93. Bruno G, De Micheli G, Fedele D, Monge L, Bonomo M, Consoli A, De Cosmo S, Di Bartolo P, Di Benedetto A, Di Cianni G, **Dotta F**, Giaccari A, Giorgino F, Grassi G, Gruden G, Mannino D, Orlandini D, Ponziani MC, Vaccaro O, Vitacolonna E. (2008) Italian standards for diabetes mellitus 2007: executive summary. *Acta Diabetol*; 45: 107-127. (I.F. 2.399)
94. Gallo R, Grieco FA, Marselli L, Ferretti E, Gulino A, Marchetti P, **Dotta F**. (2008) Hedgehog signaling during expansion of human pancreatic islet-derived precursors. *Ann NY Acad Sci*; 1150: 43-45. (I.F. 4.383)
95. **Dotta F**, Fondelli C, Falorni A. (2008) Can NK cells be a therapeutic target in human type 1 diabetes? *Eur J Immunol*; 38(11): 2961-2963. (I.F. 4.034)
96. **Dotta F**. (2009) Innate immunity and human insulinitis during beta-cell Coxsackie B4 infection. *J Med Virol*; 81: 202. (I.F. 2.347)
97. Tiberti C, Shashaj B, Verrienti A, Vecci EG, Lucantoni F, Masotti D, Morano S, Sulli N, **Dotta F**. (2009) GAD and IA-2 autoantibody detection in type 1 diabetic patient saliva. *Clin Immunol*; 131(2): 271-276. (I.F. 3.672)
98. Bosi E, **Dotta F**, Jia Y, Goodman M. (2009) Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. *Diabetes Obes Metab*; 11(5): 506-515. (I.F. 6.360)
99. Bolli G, **Dotta F**, Colin L, Minic B, Goodman M. (2009) Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. *Diabetes Obes Metab*; 11(6): 589-595. (I.F. 6.360)
100. Bonato V, Cataldo D, **Dotta F**, Carmellini M. (2009) Diagnosis and approach to posttransplant diabetes. *Curr Diab Rep*; 9(4): 317-323. (I.F. 3.080)
101. La Marca A, Marzotti S, Brozzetti A, Stabile G, Artenisio AC, Bini V, Giordano R, De Bellis A, Volpe A, Falorni A; Italian Addison Network. (2009) Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. *J Clin Endocrinol Metab*; 94(10): 3816-23. (I.F. 6.209)
102. Brozzetti A, Marzotti S, Tortoioli C, Bini V, Giordano R, **Dotta F**, Betterle C, De Bellis A, Arnaldi G, Toscano V, Arvat E, Bellastella A, Mantero F, Falorni A; Italian Addison Network. (2010) Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies. *Eur J Endocrinol*; 162(2): 361-369. (I.F. 4.069)
103. Roep BO, Kleijwegt FS, van Halteren AG, Bonato V, Boggi U, Vendrame F, Marchetti P, **Dotta F**. (2010) Islet inflammation and CXCL10 in recent-onset type 1 diabetes. *Clin Exp Immunol*; 159(3): 338-343. (I.F. 3.037)

104. Igoillo-Esteve M, Marselli L, Cunha DA, Ladrière L, Ortis F, Grieco FA, **Dotta F**, Weir GC, Marchetti P, Eizirik DL, Cnop M. (2010) Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia; 53(7): 1395-1405. **(I.F. 6.671)**
105. **Dotta F**, Galleri L, Sebastiani G, Vendrame F. (2010) Virus infections: lessons from pancreas histology. Curr Diab Rep; 10(5): 357-361. **(I.F. 3.080)**
106. Olivieri A, De Angelis S, Dionisi S, D'Annunzio G, Locatelli M, Marinaro M, Bonato V, Amendola A, Songini M, Velluzzi F, Schirru C, Cotichini R, Stazi MA, **Dotta F**, Lorini R, Bottazzo GF, Boirivant M. (2010) Serum transforming growth factor  $\beta$ 1 during diabetes development in non-obese diabetic mice and humans. Clin Exp Immunol; 162(3): 407-414. **(I.F. 3.037)**
107. Merlotti D, Gennari L, **Dotta F**, Lauro D, Nuti R. (2010) Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr Metab Cardiovasc Dis; 20(9): 683-690. **(I.F. 3.323)**
108. Gallwitz B, Haupt A, Kraus P, Peters N, Petto H, **Dotta F**, Petto H, Poll L, Rose L, Scherthaner G. (2010) Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al. Diabetes Obes Metab; 12(12): 1127-1128. **(I.F. 6.360)**
109. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group. (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010 Apr 24; 375(9724):1447-56. **(I.F. 45.217)**
110. Grieco FA, Vendrame F, Spagnuolo I, **Dotta F**. (2011) Innate immunity and the pathogenesis of type 1 diabetes. Semin Immunopathol; 33(1): 57-66. **(I.F. 7.748)**
111. Sebastiani G, Vendrame F, **Dotta F**. (2011) MicroRNAs as new tools for exploring type 1 diabetes: relevance for immunomodulation and transplantation therapy. Transplant Proc; 43(1): 330-332. **(I.F. 0.982)**
112. Falorni A, Chen S, Zanchetta R, Yu L, Tiberti C, Bacosi ML, Furmaniak J, Bini V, **Dotta F**, Eisenbarth GS, Smith BR, Betterle C. (2011) Measuring adrenal autoantibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. Clin Immunol; 140(3): 291-299. **(I.F. 3.672)**
113. Sebastiani G, Grieco FA, Spagnuolo I, Galleri L, Cataldo D, **Dotta F**. (2011) Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes Metab Res Rev; 27(8): 862-866. **(I.F. 3.553)**
114. Grieco FA, Moretti M, Sebastiani G, Galleri L, Spagnuolo I, Scafetta G, Gulino A, De Smaele E, Maroder M, **Dotta F**. (2011) Delta-cell specific expression of hedgehog pathway Ptc1 receptor in murine and human endocrine pancreas. Diabetes Metab Res Rev; 27(8): 755-760. **(I.F. 3.553)**
115. Bruno G, De Micheli A, Frontoni S, Monge L, Bonomo M, De Cosmo S, Grassi G, Nicolucci A, Aiello A, Bertuzzi F, Bonora E, Cimino A, Cordera R, de Bigontina G, Di Bartolo P, **Dotta F**, Frittitta L, Giaccari A, Giorgino F, Gruden G, Marchetti P, Meschi F, Pellegrini MA, Rivellesse A, Sesti G. (2011) Highlights from "Italian Standards of care for Diabetes Mellitus 2009-2010". Nutr Metab Cardiovasc Dis; 21(4): 302-314. **(I.F. 3.323)**
116. Tancredi M, Marselli L, Lencioni C, Masini M, Bugliani M, Suleiman M, Masiello P, Boggi U, Filipponi F, **Dotta F**, Marchetti P, Di Cianni G. (2011) Histopathology and ex vivo insulin secretion of pancreatic islets in gestational diabetes: A case report. Islets; 3(5): 231-233. **(I.F. 1.487)**
117. Tiberti C, Yu L, Lucantoni F, Panimolle F, Spagnuolo I, Lenzi A, Eisenbarth GS, **Dotta F**. (2011) Detection of four diabetes specific autoantibodies in a single radioimmunoassay: an innovative high-throughput approach for autoimmune diabetes screening. Clin Exp Immunol; 166(3): 317-324. **(I.F. 3.037)**
118. Vendrame F, **Dotta F**. (2011) Comment on: Meagher et al. Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism. Diabetes 2010;59:2862-2871. Diabetes; 60(2): e12. **(I.F. 8.095)**

119. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Cavalot F, Cignarelli M, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. (2011) Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens; 29(9): 1802-9. **(I.F. 4.720)**
120. Nicolucci A, Del Prato S, Vespasiani G; ELEONOR Study Group. (2011) Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction. Diabetes Care; 34(12): 2524-6. **(I.F. 8.420)**
121. Grieco FA, Sebastiani G, Spagnuolo I, Patti A, **Dotta F.** (2012) Immunology in the clinic review series; focus on type 1 diabetes and viruses: how viral infections modulate beta cell function. Clin Exp Immunol; 168(1): 24-29. **(I.F. 3.037)**
122. Vendrame F, Cataldo D, Ciarlo L, Umland O, Misasi R, **Dotta F.** (2012) In type 1 diabetes immunocompetent cells are defective in IL-16 secretion. Scand J Immunol; 75(1): 127-128. **(I.F. 1.739)**
123. Coppieters KT, **Dotta F,** Amirian N, Campbell PD, Kay TW, Atkinson MA, Roep BO, von Herrath MG. (2012) Demonstration of islet-autoreactive CD8 T cells in insulinitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med; 209(1): 51-60. **(I.F. 12.515)**
124. Del Prato S, Nicolucci A, Lovagnini-Scher AC, Turco S, Leotta S, Vespasiani G; ELEONOR Study Group. (2012) Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study. Diabetes Technol Ther; 14(2): 175-82. **(I.F. 2.106)**
125. Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK; DURATION-4 Study Group (2012) Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care; 35(2): 252-8. **(I.F. 8.420)**
126. Gallo R, Natale M, Vendrame F, Boggi U, Filipponi F, Marchetti P, Laghi Pasini F, **Dotta F.** (2012) In vitro effects of mycophenolic acid on survival, function, and gene expression of pancreatic beta-cells. Acta Diabetol; 49 Suppl 1: S123-31. PMID: 22249339. **(I.F. 2.399)**
127. Guarino E, Nigi L, Patti A, Fondelli C, **Dotta F.** (2012) Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opin Pharmacother; 13(9): 1377-84. **(I.F. 3.534)**
128. Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabrò A, Cataldo D, Stolakis K, **Dotta F,** Nuti R. (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab; 97(5): 1737-1744. **(I.F. 6.209)**
129. Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, Galleri L, Spagnuolo I, Steidler L, Van Huynegem K, Demetter P, Wasserfall C, Atkinson MA, **Dotta F,** Rottiers P, Gysemans C, Mathieu C. (2012) Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified *Lactococcus lactis* in mice. J Clin Invest; 122(5): 1717-1725. **(I.F. 13.215)**
130. Gallwitz B, Guzman J, **Dotta F,** Guerci B, Simò R, Basson BR, Festa A, Kiljanski J, Sapin H, Trautmann M, Schernthaner G. (2012) Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet; 379(9833): 2270-2278. **(I.F. 45.217)**
131. Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, Grieco FA, Del Guerra S, D'Aleo V, Piro S, Marselli L, Boggi U, Filipponi F, Tinti L, Salvini L, Wollheim CB, Purrello F, **Dotta F.** (2012) A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia; 55(12): 3262-3272. **(I.F. 6.671)**
132. Galleri L, Sebastiani G, Vendrame F, Grieco FA, Spagnuolo I, **Dotta F.** (2012) Viral Infections and Diabetes. Adv Exp Med Biol; 771: 252-271. **(I.F. 1.958)**
133. Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellese AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial). (2012) Addition of either pioglitazone or a

sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutr Metab Cardiovasc Dis; 22(11): 997-1006. **(I.F. 3.323)**

134. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaidis M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTITUDE Investigators (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med; 367(23): 2204-13. **(I.F. 55.873)**
135. Rissanen A, Howard CP, Botha J, Thuren T, for the Global Investigators (2012) Effect of anti-IL-1 $\beta$  antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metabol; 14:1088-1096. **(I.F. 6.360)**
136. Valle A, Giamporcaro GM, Scavini M, Stabilini A, Grogan P, Bianconi E, Sebastiani G, Masini M, Maugeri N, Porretti L, Bonfanti R, Meschi F, De Pellegrin M, Lesma A, Rossini S, Piemonti L, Marchetti P, **Dotta F**, Bosi E, Battaglia M. (2013) Reduced circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes; 62(6): 2072-77. **(I.F. 8.095)**
137. Sebastiani G, Nigi L, Spagnuolo I, Morganti E, Fondelli C, **Dotta F**. (2013) MicroRNA profiling in sera of patients with type 2 diabetes mellitus reveals an upregulation of miR-31 expression in subjects with microvascular complications. J Biomedical Science and Engineering (JBSE); 6: 58-64. **(I.F. 0.31)**
138. Tortosa F, **Dotta F**. (2013) Incretin hormones and beta-cell mass expansion: what we know and what is missing? Arch Physiol Biochem; 119(4):161-169. **(I.F. 1.763)**
139. Patti A, Gennari L, Merlotti D, **Dotta F**, Nuti R. (2013) Endocrine actions of osteocalcin. Int J Endocrinol; 2013:846480. **(I.F. 1.948)**
140. Spagnuolo I, Patti A, Sebastiani G, Nigi L, **Dotta F**. (2013) The case for virus-induced type 1 diabetes. Curr Opin Endocrinol Diabetes Obes; 20(4):292-8. **(I.F. 3.367)**
141. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Morano S, Cavalot F, Lamacchia O, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events Study Group. (2013) HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes care; 36(8): 2301-10. **(I.F. 8.420)**
142. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) study group. (2013) Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study. J Intern Med; 274(2): 176-191. **(I.F. 6.063)**
143. Bosi E, Scavini M, Ceriello A, Cucinotta D, Tiengo A, Marino R, Bonizzoni E, Giorgino F; PRISMA Study Group. (2013) Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial. Diabetes Care; 36(10): 2887-94. **(I.F. 8.420)**
144. Ceccarelli E, Guarino E, Merlotti D, Patti A, Gennari L, Nuti R, **Dotta F**. (2013) Beyond glycemic control in diabetes mellitus: effects of incretin-based therapy on bone metabolism. Front Endocrinol; doi:10.3389/fendo.2013.00073; 4(73): 1-12.
145. Grieco FA, Moore F, Vigneron F, Santin I, Villate O, Marselli L, Rondas D, Overbergh L, **Dotta F**, Marchetti P, Mathieu C, Eizirik DL. (2013) IL-17A increases the expression of pro-inflammatory chemokines in human pancreatic islets. Diabetologia; 57(3): 502-511. **(I.F. 6.671)**
146. Mannucci E, Genovese S, Monami M, Navalesi G, **Dotta F**, Anichini R, Romagnoli F, Gensini G. (2014) Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study. The D.A.N.T.E. (Diabetic ulcer Antimicrobial New Topical treatment Evaluation) Study. Acta Diabetol; 51(3): 435-40. **(I.F. 2.399)**
147. Tiberti C, Panimolle F, Bonamico M, Filardi T, Pallotta L, Nenna R, Pontone S, **Dotta F**, Pugliese G, Lenzi A, Balducci S, Morano S. (2014) Long-standing type 1 diabetes: patients with adult-onset develop

celiac-specific immunoreactivity more frequently than patients with childhood-onset diabetes, in a disease duration-dependent manner. *Acta Diabetol*; 51(4):675-8. (I.F. 2.399)

148. **Dotta F**, Sebastiani G. (2014) Enteroviral infections and development of type 1 diabetes: The Brothers Karamazov within the CVBs. *Diabetes*; 63(2): 384-6. (I.F. 8.095)
149. Takiishi T, Ding L, Baeke F, Spagnuolo I, Sebastiani G, Laureys J, Verstuyf A, Carmeliet G, **Dotta F**, Van Belle T, Gysemans C, Mathieu C. (2014) □Dietary supplementation with high doses of regular vitamin D3 safely reduces Diabetes incidence in nod mice when given early and long-term. *Diabetes*; 63(6): 2026-36. (I.F. 8.095)
150. Robert S, Gysemans C, Takiishi T, Korf H, Spagnuolo I, Sebastiani G, Van Huynegem K, Steidler L, Caluwaerts S, Demetter P, Wasserfall CH, Atkinson MA, **Dotta F**, Rottiers P, Van Belle TL, Mathieu C. (2014) Oral delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by *Lactococcus lactis* reverses diabetes in recent-onset NOD mice. *Diabetes*; 63(8): 2876-87. (I.F. 8.095)
151. Pugliese G, Solini A, Bonora E, Orsi E, Zerbini G, Fondelli C, Gruden G, Cavalot F, Lamacchia O, Trevisan R, Vedovato M, Penno G; RIACE Study Group. (2014) Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. *Cardiovasc Diabetol*;13(1): 59. (I.F. 4.015)
152. Cantara S, Pilli T, Sebastiani G, Cevenini G, Busonero G, Cardinale S, **Dotta F**, Pacini F. (2014) Circulating miRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population. *J Clin Endocr Metab*;99(11):4190-8. (I.F. 6.209)
153. Pugliese G, Solini A, Bonora E, Fondelli C, Orsi E, Nicolucci A, Penno G, RIACE Study Group. (2014) Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. *Nutr Metab Cardiovasc Dis*; 24(8): 815-22. (I.F. 3.323)
154. Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K, Meininger G; DIA3004 Study Group. (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. *Diabetes Obes Metab*; 16(10):1016-27. (I.F. 6.360)
155. Sebastiani G, Po A, Miele E, Ventriglia G, Ceccarelli E, Bugliani M, Marselli L, Marchetti P, Gulino A, Ferretti E, **Dotta F**. (2014) MicroRNA-124a is hyperexpressed in type-2 diabetic human pancreatic islets and negatively regulates insulin secretion. *Acta Diabetol*; 52(3):523-30. (I.F. 2.399)
156. Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators. (2014) Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. *Lancet Diabetes Endocrinol*;2(11):885-93. (I.F. 9.185)
157. Zampetti S, Campagna G, Tiberti C, Songini M, Arpi ML, De Simone G, Cossu E, Cocco L, Osborn J, Bosi E, Giorgino F, Spoletini M, Buzzetti R; NIRAD Study Group. (2014) High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). *Eur J Endocrinol*;171(6):697-704. (I.F. 4.069)
158. Mathieu C, Overbergh L, Badenhoop K, Bingley P, Dayan C, Demengeot J, **Dotta F**, Eizirik D, Lenzen S, Marchetti P, Peakman M, Roep B, Todd J, Rottiers P, Megit S. (2014) The story of NAIMIT – A framework 7 project on type 1 diabetes. *Eur Endocrinol*;10(2):100-105.
159. Buzzetti R, Spoletini ML, Zampetti S, Campagna G, Marandola L, Panimolle F, **Dotta F**, Tiberti C for the NIRAD Study Group (NIRAD 8). (2015) Tyrosine phosphatase-related islet antigen 2 (IA-2)<sub>(256-760)</sub> antibody identifies autoimmunity in obese type 2 diabetes subjects. *Diabetes Care*; 38(3):513-20. (I.F. 8.420)
160. Nicolucci A, Pintaudi B, Rossi MC, Messina R, **Dotta F**, Frontoni S, Caputo S, Lauro R. (2015) The social burden of Hypoglycemia in the elderly. *Acta Diabetol*; 52(4):677-85. (I.F. 2.399)
161. Pellegrini S, Ungaro F, Mercalli A, Melzi R, Sebastiani G, **Dotta F**, Broccoli V, Piemonti L, Sordi V.

- (2015) Human induced pluripotent stem cells differentiate into insulin-producing cells able to engraft in vivo. Acta Diabetol; 52(6):1025-35. **(I.F. 2.399)**
162. Scherthaner G, Rosas-Guzmán J, **Dotta F**, Guerci B, Simó R, Festa A, Kiljański J, Zhou M, Gallwitz B. (2015) Treatment escalation options for patients with type 2 diabetes after failure of exenatide BID or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) Study. Diabetes Obes Metabol; 17(7):689-698. **(I.F. 6.360)**
163. Ventriglia G, Nigi L, Sebastiani G, **Dotta F**. (2015) MicroRNAs: novel players in the dialogue between pancreatic islets and immune system in autoimmune diabetes. Biomed Res Int; 2015: 749734. **(I.F. 1.579)**
164. Sebastiani G, Mancarella F, Ventriglia G, Nigi L, Valentini M, Grieco GE, **Dotta F**. (2015) MicroRNA miR-124a, a negative regulator of insulin secretion, is hyperexpressed in human pancreatic islets of type 2 diabetic patients. RNA & DISEASE; 2: e593. DOI: 10.14800/rd.593.
165. Simó R, Guerci B, Scherthaner G, Gallwitz B, Rosas-Guzmán J, **Dotta F**, Festa A, Zhou M, Kiljański J. (2015) Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovasc Diabetol; 14:116. DOI 10.1186/s12933-015-0279-z. **(I.F. 4.02)**
166. Martino L, Masini M, Bugliani M, Marselli L, Suleiman M, Boggi U, Nogueira TC, Filipponi F, Occhipinti M, Campani D, **Dotta F**, Syed F, Eizirik DL, Marchetti P, De Tata V. (2015) Mast cells infiltrate pancreatic islets in human type 1 diabetes. Diabetologia; 58(11):2554-62. **(I.F. 6.671)**
167. Battaglia M, Nigi L, **Dotta F**. (2015) Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset? Curr Diab Rep;15(12):115. doi: 10.1007/s11892-015-0690-6. **(I.F. 3.080)**
168. Belba A, Cortelazzo A, Giansanti A, Durante J, Nigi L, **Dotta F**, Timperio AM, Zolla L, Leoncini R, Guerranti R, Ponchiotti R. (2016) Erectile dysfunction and diabetes: association with the impairment of lipid metabolism and oxidative Stress. Clin Biochem; 49(1):70-78. **(I.F. 2.275)**
169. Laiho JE, Oikarinen M, Richardson SJ, Frisk G, Nyalwidhe J, Burch TC, Morris MA, Oikarinen S, Pugliese A, **Dotta F**, Campbell-Thompson M, Nadler J, Morgan NG, Hyöty H, JDRF nPOD-Virus Group. (2016) Relative sensitivity of immunohistochemistry, multiple reaction monitoring mass spectrometry, *in situ* hybridization and PCR to detect Coxsackievirus B1 in A549 cells. (2016) J Clin Virol; 77: 21-28. **(I.F. 3.016)**